Mar 16, 2020
The Global Shingles Vaccine Market is expected to grow by USD 1.08 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period
Mar 10, 2020
First QS-21 Royalty Payment Due to Agenus is Triggered
Mar 26, 2019
NanoViricides has Requested a Pre-IND Meeting with the US FDA
Jan 03, 2019
Agenus Awarded Grant to Enable QS-21 Innovations
Nov 05, 2018
Curevo Announces FDA Advancement of IND Application for CRV-101, New Shingles Vaccine Candidate
Sep 28, 2018
NanoViricides Inc. to Present at the MicroCap Conference in New York City on October 1
Sep 05, 2018
Over 50? You Need This Vaccine to Protect Your Vision
Sep 05, 2018
NanoViricides Inc. to Present at 20th Annual Rodman & Renshaw Conference in NYC on Sept 6th
Aug 01, 2018
Family Physicians: Shingles Vaccine for Adults 50+, Don't Delay
Jun 12, 2018
Survey Finds Less than Two-Thirds of Americans (62%) Know a Preventive Vaccine is Available for Shingles
May 03, 2018
VACCINE SALES MARKET FORECAST 2018-2028
May 01, 2018
Lawsuit Alleges Widely-Used Shingles Vaccine Caused Permanent Loss of Eyesight
Apr 18, 2018
New Study: Patients Could Save Time and Money If Neighborhood Pharmacies Can Administer More Vaccines
Mar 16, 2018
CVS Pharmacy Now Offering New Shingles Vaccine at Locations Nationwide
Dec 06, 2017
Nanoviricides Initiates a Safety/Toxicology Study of Its Leading Shingles Candidates
Nov 07, 2017
Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Oct 25, 2017
CDC's Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
Oct 25, 2017
Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles
Oct 20, 2017
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Oct 20, 2017
FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant